Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356196 | 0.98 | CYP1A2 (0.32) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5078995 | 0.81 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL153625 | 0.81 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL1071947 | 0.81 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| SCHEMBL2568072 | 0.78 | CYP1A2 (0.38) | CYP1A2CYP2D6 | |
| SCHEMBL34280 | 0.78 | CYP1A2 (0.38) | CYP1A2CYP2D6 | |
| SCHEMBL252711 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL6017809 | 0.77 | CYP1A2 (0.32) | CYP1A2CYP2D6 | |
| Carbimide SCHEMBL7717116 | 0.76 | CYP1A2 (0.33) | CYP1A2CYP2D6 | |
| SCHEMBL9725035 | 0.76 | TRPA1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6080563-A | RADICAL-MEDIATED DECARBOXYLATION OF PERACETYLATED N-ACETYLNEURAMINIC ACID BY MIXING WITH 1.0 EQUIVALENT OF ETHYL(DIETHYLAMINO)PROPYLCARBODIIMIDE HYDROCHLORIDE IN PRESENCE OF EXCESS OF THIOHYDROXAMATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2000-06-27 | — | — | US | claimed |
| US-20200347450-A1 | Parallel Polymer Sequencing Methods | MIR KALIM U (US) | 2020-11-05 | — | — | US | disclosed |
| US-20190136312-A1 | Parallel Polymer Sequencing Methods | MIR KALIM U (US) | 2019-05-09 | — | — | US | disclosed |
| EP-2914607-B1 | PHOTOCLEAVABLE LINKER MOLECULES WITH DIARYLSULPHID BACKBONE FOR TRANSIENT BIOCONJUGATE SYNTHESIS | VENTANA MED SYST INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9790243-B2 | Photocleavable linker molecules with diarylsulphide backbone for transient bioconjugate synthesis | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160040227-A1 | PARALLEL POLYMER SEQUENCING METHODS | MIR KALIM U (US) | 2016-02-11 | — | — | US | disclosed |
| US-20150284415-A1 | PHOTOCLEAVABLE LINKER MOLECULES WITH DIARYLSULPHID BACKBONE FOR TRANSIENT BIOCONJUGATE SYNTHESIS | VENTANA MED SYST INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20140162892-A1 | Parallel polymer sequencing mothods | MIR KALIM U (GB) | 2014-06-12 | — | — | US | disclosed |
| EP-2431481-A1 | Parallel polymer sequencing methods | Mir, Kalim (GB) | 2012-03-21 | — | — | EP | disclosed |
| EP-1689881-B1 | PARALLEL NUCLEIC ACID SEQUENCING METHODS | ISIS INNOVATION (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2002053780-A2 | 5'-THIO PHOSPHATE DIRECTED LIGATION OF OLIGONUCLEOTIDES AND USE IN DETECTION OF SINGLE NUCLEOTIDE POLYMORPHISMS | MOLECULAR STAGING, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| EP-0731091-B1 | 2-OXOINDOLINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5807883-A | GASTROINTESTINAL DISORDERS; PANCREATITIS | TANABE SEIYAKU CO., LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0731091-A1 | 2-OXOINDOLINE DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 1996-09-11 | — | — | EP | disclosed |
| EP-0486478-A2 | Renin-inhibiting peptides | THE UPJOHN COMPANY (US) | 1992-05-20 | — | — | EP | disclosed |
| US-4880781-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0173481-A2 | Peptides | THE UPJOHN COMPANY (US) | 1986-03-05 | — | — | EP | disclosed |
| US-4110432-A | PROPHYLAXIS | BURROUGHS WELLCOME CO. (US) | 1978-08-29 | — | — | US | disclosed |
| US-4087283-A | CARBODIIMIDE AND N-HYDROXY CYCLIC AMINE | GAF CORPORATION (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284415-A1 | PHOTOCLEAVABLE LINKER MOLECULES WITH DIARYLSULPHID BACKBONE FOR TRANSIENT BIOCONJUGATE SYNTHESIS | DHFR, DTYMK, DNPEP | CYP1A2 4303/4885CYP2D6 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.